BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the pricing of its upsized initial public offering of 17,650,000 shares of its common stock at a price to the public of $18.00 per share. In addition, Aktis has granted the underwriters a 30-day option to purchas ...